Lyell Immunopharma is a developer of curative cell-based immunotherapies for any cancer, with a focus on CAR-Ts and solid tumors.

Register for Details

For more details on financing and valuation for Lyell, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Lyell's ticker symbol?

LYEL

What is Lyell's stock price?

2.19 as of 3/27/23

Learn more about Lyell

Forge green plus iconForge green minus icon

What is Lyell funding to date?

Lyell has raised $358MM.
Forge green plus iconForge green minus icon

When was Lyell founded?

Lyell was founded in 2018.